Highlights from Maui Derm 2024
The Maui Derm 2024 Conference showcased groundbreaking advancements in skin care, innovative treatments, new therapies, and cutting-edge research.
The Maui Derm 2024 Conference showcased a wide array of advancements in dermatology, from innovative treatments to exciting new therapies, to business opportunities to the latest research. Here, Practical Dermatology recaps the highlights and insights from the show:
What's New in Topical Treatment for Plaque Psoriasis?
Linda Stein Gold, MD, director of dermatology clinical research at Henry Ford Health, discusses what’s new in topical treatment of plaque psoriasis and the importance of an “elegant vehicle” for patients to use in their care regimens.
Energy-based Devices for Fat Reduction
Michael H. Gold, MD, founder and medical director of the Gold Skin Care Center in Nashville, highlights new energy-based devices for fat reduction, including those utilizing lasers and radio frequency technology for muscle stimulation.
Important FDA Approvals in 2023 Lead to New, Exciting Treatments in 2024
A slew of big approvals for new therapies in 2023 has increased the armamentarium for dermatologists treating many conditions going into 2024, according to an opening presentation at Maui Derm 2024.
ARCADIA 1 and 2: Nemolizumab Reduces Itch, Sleep Disturbance in Atopic Dermatitis
Patients showed significant improvements in the primary and secondary endpoints.
Interim Analysis: Tralokinumab Improves Quality of Life in Moderate-to-Severe Atopic Dermatitis
Tralokinumab, an interleukin-13 (IL-13) inhibitor approved for the treatment of moderate-to-severe atopic dermatitis (AD) in adults, was shown to improve several quality of life measures, a 6-month interim analysis suggests.
Long-Term Analysis Shows Upadacitinib Safe Up to 5 Years for Moderate to Severe AD
Upadacitinib for the treatment of moderate-to-severe atopic dermatitis (AD) was shown to have an acceptable safety profile at 5 years, according to a new integrated analysis.
Deucravacitinib Shows Sustained Response, Safety Profile: Analyses
The TYK2 inhibitor may have applications beyond psoriasis.
BE HEARD Analysis: Bimekizumab Maintains Treatment Response at 48 Weeks in HS
Patients responsive to the treatment tended to maintain the response over time.
Analysis: Upadacitinib Improves Night-time Itch and Sleep Disturbance
Results from a new analysis presented at Maui Derm 2024 indicated that upadacitinib improves night-time itch and sleep disturbance.
Guselkumab Demonstrates Significant and Rapid Scalp Psoriasis Clearance in People of Color
First-of-its-kind study presented at Maui Derm 2024 adds to growing body of evidence demonstrating that TREMFYA® is effective for adults with moderate to severe plaque psoriasis across all skin tones.